Eltrombopag-Associated Acneiform Rash: A Case Report No abstract available

Automated Insulin Delivery: The Artificial Pancreas Technical Challenges Background: The automation of glucose control has been an important goal of diabetes treatment for many decades. The first artificial pancreas experiences were in-hospital, closely supervised, small-scale, and short-term studies that demonstrated their superiority over continuous subcutaneous insulin infusion therapy. At present, long-term outpatient studies are being conducted in free-living scenarios. Areas of Uncertainty: The integration of multiple devices increases patients' burden and the probability of technical risks. Control algorithms must be robust to manage disturbance variables, such as physical exercise, meal composition, stress, illness, and circadian variations in insulin sensitivity. Extra layers of safety could be achieved through remote supervision. Dual-hormone systems reduce the incidence and duration of hypoglycemia, but the availability of stable pumpable glucagon needs to be solved. Faster insulin analogues are expected to improve all types of artificial pancreas. Therapeutic Advances: Artificial pancreas safety and feasibility are being demonstrated in outpatient studies. Artificial pancreas use increases the time of sensor-measured glucose in near-normoglycemia and reduces the risk of hyperglycemia and hypoglycemia. The benefits are observed both in single- and dual-hormone algorithms and in full- or semi-closed loop control. A recent meta-analysis including 41 randomized controlled trials showed that artificial pancreas use achieves a reduction of time in hyperglycemia (2 hours less than control treatment) and in hypoglycemia (20 minutes less); mean levels of continuous glucose sensor fell by 8.6 mg/dL over 24 hours and by 14.6 mg/dL overnight. The OpenAPS community uses Do It Yourself artificial pancreas in the real world since 2013, and a recent retrospective cross-over study (n = 20) compared continuous glucose sensor readings before and after initiation: mean levels of blood glucose fell by 7.4 mg/dL over 24 hours and time in range increased from 75.8% to 82.2% (92 minutes more). Conclusions: The outpatient use of artificial pancreas is safe and improves glucose control in outpatients with type 1 diabetes compared with the use of any type of insulin-based treatment. The availability of open-source solutions and data sharing is needed to foster the development of new artificial pancreas approaches and to promote the wide use of Big Data tools for knowledge discovery, decision support, and personalization. Address for correspondence: ETSI Telecomunicación, Avda. Complutense 30, 28040 Madrid, Spain. E-mail: mariaelena.hernando@gbt.tfo.upm.es This work was partly supported by a research grant from the Spanish Ministry of Health cofunded by FEDER: FIT-CLOOP (FIS PI14/00109). The authors have no conflicts of interest to declare. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Is Insulin Therapy Safe? Background: After 98 years of insulin therapy, issues of safety remain of concern. Areas of Uncertainty: Uncertainty has been expressed variously in regard of arterial cell wall proliferation, promotion of proliferative retinopathy, promotion of tumor growth, and for pregnancy. Immunological issues have been little studied since the advent of highly purified insulins in the 1970s. A specific topic is whether hypoglycemia, severe or otherwise, might promote cardiac thrombotic or dysrhythmic events. Data Sources: A literature review in these areas is difficult because nearly all clinical trials with insulin refer to adverse events. However, the specific topics aforementioned allow for some informed literature searching supplemented by finger-searching of published articles, notably in connection with the insulin analogues. Therapeutic Understandings: Safety data for pregnancy are weak because of power problems, but there are no signals for added maternal or fetal risk. Clinical-outcome trials that assess insulin against other glucose-lowering therapies or with significantly different insulin preparations in different arms are few and are sometimes conducted at modest dosage but fail to suggest promotion of arterial disease. Concern over growth-promoting activity of insulin glargine turned out to be ill-founded when the circulating moiety after injection was noted to have a lower IGF-1:insulin activity than human insulin, and a direct study of retinopathy progression or meta-analysis of malignancy incidence failed to show signals of concern. It does seem that severe hypoglycemia can cause death in some people with type 1 diabetes, although the tissue mechanism is unknown, but reducing severe hypoglycemia in type 2 diabetes does not protect against arterial events. Both symptomatic and severe hypoglycemia can however be reduced by use of more recently marketed insulin analogues, and this improves tolerability if not safety. Conclusions: In conclusion, although insulin therapy clearly gives health benefits, the evidence for long-term harm is absent or weak. Address for correspondence: Professor, Institute for Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom. E-mail: philip.home@newcastle.ac.uk The authors presented some of the materials discussed to the meeting of the EASD D&CVD Study Group, June 12, 2018, Herzliya, Israel. PDH or institutions with which he is associated have received funding for his advisory, research, or lecturing activities from the manufacturers of all the human insulins and insulin analogues discussed including Antriabio, Biocon, Eli Lilly, Hanmi, Novo Nordisk, and Sanofi. B. Itzhak has received funding for his advisory, research, or lecturing activities from Eli Lilly, NovoNordisk, and Sanofi, and manufacturers of noninsulin glucose-lowering medications. Both authors contributed to the literature identification, synthesis, and writing of this manuscript. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Rapid Titration of Clozapine in Schizophrenia and Bipolar Disorder Despite evidence accumulated over 30 years of clozapine efficacy in schizophrenia, its use is suboptimal. Long duration of standard titration and monitoring procedures are strong barriers in clozapine prescribing. The aim of the present paper is to discuss the challenges of rapid clozapine titration. The currently approved/recommended titration methods in US, Europe, and Australia are discussed. The rapid clozapine titration was introduced in our hospital in the early 2000's as “last resort” method for aggressive, belligerent or homicidal patients with schizophrenia and bipolar disorder. In our opinion, rapid clozapine titration might shorten the duration of patient and family suffering associated with uncontrolled psychotic symptoms, reduce the need and risks associated with polypharmacy, and reduce the costs of health care services of prolonged hospitalization. As there are no randomized controlled clinical trials to compare the efficacy and safety of standard versus rapid titration of clozapine in schizophrenia or bipolar disorder, future studies are needed. Address for correspondence: E-mail: lorena.dima@unitbv.ro. The authors have no conflicts of interest to declare. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Eczematous Drug Eruption Induced by Sofosbuvir/Velpatasvir: The Need for a Better Classification No abstract available

Amitriptyline-Induced Acute Kidney Injury and Acute Hepatitis: A Case Report No abstract available

Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide, although important advances in target therapy have been developed in the past few years. Erlotinib is a reversible epidermal growth factor receptor (EGFR) inhibitor, which was approved at its maximum tolerated dose of 150 mg/d determined from the initial phase I study. Studies suggest that the optimal biological dose of erlotinib should be lower and dependent on different variables. Study Question: We aimed to evaluate the response rates and toxicity with 75 mg/d dose of erlotinib in South American patients. Method: We performed a retrospective review of 18 patients with histologically proven (+) EGFR (+) mutation metastatic NSCLC (mNSCLC) treated with 75 mg/d erlotinib as starting dose. Measures and Outcomes: Clinical information, including toxicity grade 1–4, drug discontinuation, clinical evolution and radiological evaluation, and overall survival (OS), was revised. Results: Patients received 75 mg/d of erlotinib as starting dose. Sixteen (89%) patients were treated in first-line treatment and 2 (11%) in second-line treatment. Mean age was 62 years (range 36–89 years), and 50% patients were female. Sixteen percent of the patients had brain metastases at first diagnosis. All patients had mutation positive EGFR, 12 (66%) had Del19 and 6 (34%) exon 21 mutation. Median progression-free survival was 17 months and OS 23 months. The main grade 1–2 toxicities were rash (44%) and diarrhea (22%). No grade 3–4 toxicity and no cases of drug discontinuation were reported. Conclusions: In South American population with mutated mNSCLC, a dose of 75 mg/d of erlotinib was well tolerated. This dose resulted in comparable benefits in progression-free survival and OS when compared to those reported in the literature with the standard dose. More studies are needed to explore the use of adjusted doses of biological agents in different ethnic backgrounds. Address for correspondence: Medical Oncology Service, Clinica Universidad los Andes, Centro de Investigación Clínica, Bradford Hill, Manzano 343, Recoleta, Santiago, Chile. E-mail: mauricioburotto@gmail.com The authors have no conflicts of interest to declare. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Dabigatran-Associated Diffuse Alveolar Hemorrhage No abstract available

Carboplatin-Induced Kounis Syndrome No abstract available

Albumin Infusion Leading to Circulatory Overload No abstract available